A population-based study of immunohistochemical detection of p53 alteration in bladder cancer
Open Access
- 6 April 2004
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (8) , 1572-1576
- https://doi.org/10.1038/sj.bjc.6601748
Abstract
The molecular pathology of bladder cancer has been the subject of considerable interest and mutation of the p53 gene, which has been associated with more invasive bladder cancer, has been widely studied. Further, there is evidence that p53 inactivation (either mutation or protein dysregulation), independent of stage, may be predictive of bladder cancer progression. In an effort to avoid possible biases associated with selection of more advanced cases, we examined p53 inactivation in a population-based study of bladder cancer in New Hampshire, using both mutation and immunohistochemical methods. We found the overall prevalence of mutation to be approximately 10%, while immunohistochemical analysis suggests that approximately 66% of the tumours have dysregulated p53 at the protein level. There was a significant association of mutation with persistent p53 staining, but there remained a marked number of tumours discordant for mutation and aberrant p53 immunohistochemistry. Based upon immunohistochemical staining alone, intensity rather than extent of p53 staining was more strongly related to tumour invasiveness. Additionally, all tumours with a mutation in exon 8 stained intensely. Taken together, this suggests that intense staining represents a distinct phenotype of dysfunctional protein. Our data indicate that population-based approaches to somatic alteration of p53 in bladder cancer are crucial to understanding the relationship of p53 changes to aetiology and the outcome of this disease, and further suggest that the pattern of immunohistochemical staining may represent distinct, discernible phenotypes.Keywords
This publication has 23 references indexed in Scilit:
- Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinomaBritish Journal of Cancer, 2003
- Expectant Management of Small, Recurrent, Noninvasive Papillary Bladder TumorsJournal of Urology, 2003
- The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder CancerJournal of Urology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcomeInternational Urology and Nephrology, 2002
- Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.International Journal of Oncology, 2000
- Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population.Environmental Health Perspectives, 1998
- p53 mutations in human bladder cancer: Genotypic versus phenotypic patternsInternational Journal of Cancer, 1994
- Prevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with SarcomaNew England Journal of Medicine, 1992
- Identification of p53 Gene Mutations in Bladder Cancers and Urine SamplesScience, 1991